Effect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP.
D000328:Adult; D001714:Bipolar Disorder / Q000188:drug therapy / Q000201:enzymology; D006152:Cyclic GMP / Q000097:blood*; D003863:Depression / Q000139:chemically induced* / Q000201:enzymology / Q000517:prevention & control; D005260:Female; D006162:Guanylate Cyclase / Q000097:blood; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D010830:Physostigmine / Q000009:adverse effects*
D008094:Lithium; D010830:Physostigmine; D006162:Guanylate Cyclase; D006152:Cyclic GMP